Articlenpj biomedical innovations2025
Indoleamine 2,3-dioxygenase-galectin-3 fusion protein remodels inflammatory and fibrotic programs, ameliorating imiquimod-induced psoriasis.
Article in npj biomedical innovations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating PEG-indoleamine 2,3-dioxygenase ameliorates diverse inflammatory diseases without toxicity or compromising immunocompetence.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Localized anti-inflammatory treatment options for psoriasis are limited. Addressing this, a fusion protein was created consisting of the regulatory enzyme indoleamine 2,3-dioxygenase (IDO) fused to carbohydrate-binding protein galectin-3 (Gal3), termed IDO-Gal3, and therapeutic potential was investigated in a murine model of imiquimod-induced psoriasis. Prior work established that Gal3 fusion provides prolonged localized tissue retention of injected fusion protein, which colocalizes therapeutic to the site of inflammation, limits systemic distribution, and reduces potential for off-target side-effects. A single subcutaneous administration at disease onset remarkably decreased the disease metrics of skin redness, scaling and thickening, as measured by the psoriasis area and severity index (PASI) composite score. Infiltrating immune cells, particularly neutrophils and gamma delta T cells, and inflammatory responses were significantly reduced. Transcriptomic analyses indicated inflammation and fibrosis-associated programs were also substantially reduced following IDO-Gal3 treatment. These data demonstrate IDO-Gal3 treatment ameliorated psoriasis with concomitant remodeling of inflammatory and fibrotic programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.